Show simple item record

dc.contributor.authorMiddelberg, Anton PJ
dc.contributor.authorRivera-Hernandez, Tania
dc.contributor.authorWibowo, Nani
dc.contributor.authorLua, Linda HL
dc.contributor.authorFan, Yuanyuan
dc.contributor.authorMagor, Graham
dc.contributor.authorChang, Cindy
dc.contributor.authorChuan, Yap P
dc.contributor.authorGood, Michael F
dc.contributor.authorBatzloff, Michael R
dc.date.accessioned2017-10-26T01:31:22Z
dc.date.available2017-10-26T01:31:22Z
dc.date.issued2011
dc.date.modified2012-03-21T23:15:02Z
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/j.vaccine.2011.05.075
dc.identifier.urihttp://hdl.handle.net/10072/43770
dc.description.abstractStudies on a platform technology able to deliver low-cost viral capsomeres and virus-like particles are described. The technology involves expression of the VP1 structural protein from murine polyomavirus (MuPyV) in Escherichia coli, followed by purification using scaleable units and optional cell-free VLP assembly. Two insertion sites on the surface of MuPyV VP1 are exploited for the presentation of the M2e antigen from influenza and the J8 peptide from Group A Streptococcus (GAS). Results from testing on mice following subcutaneous administration demonstrate that VLPs are self adjuvating, that adding adjuvant to VLPs provides no significant benefit in terms of antibody titre, and that adjuvanted capsomeres induce an antibody titre comparable to VLPs but superior to unadjuvanted capsomere formulations. Antibodies raised against GAS J8 peptide following immunization with chimeric J8-VP1 VLPs are bactericidal against a GAS reference strain. E. coli is easily and widely cultivated, and well understood, and delivers unparalleled volumetric productivity in industrial bioreactors. Indeed, recent results demonstrate that MuPyV VP1 can be produced in bioreactors at multi-gram-per-litre levels. The platform technology described here therefore has the potential to deliver safe and efficacious vaccine, quickly and cost effectively, at distributed manufacturing sites including those in less developed countries. Additionally, the unique advantages of VLPs including their stability on freeze drying, and the potential for intradermal and intranasal administration, suggest this technology may be suited to numerous diseases where adequate response requires large-scale and low-cost vaccine manufacture, in a way that is rapidly adaptable to temporal or geographical variation in pathogen molecular composition.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom7154
dc.relation.ispartofpageto7162
dc.relation.ispartofissue41
dc.relation.ispartofjournalVaccine
dc.relation.ispartofvolume29
dc.rights.retentionY
dc.subject.fieldofresearchBiological sciences
dc.subject.fieldofresearchInfectious agents
dc.subject.fieldofresearchAgricultural, veterinary and food sciences
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.subject.fieldofresearchcode31
dc.subject.fieldofresearchcode310702
dc.subject.fieldofresearchcode30
dc.subject.fieldofresearchcode32
dc.titleA microbial platform for rapid and low-cost virus-like particle and capsomere vaccines
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2011
gro.hasfulltextNo Full Text
gro.griffith.authorGood, Michael F.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record